🔗 Share this article

While America continues making sweeping changes to its vaccine recommendations, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by casting doubt on coronavirus vaccines in the pandemic and has focused upon potential fatalities following Covid immunization in her brief time at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to unveil major changes to the pediatric immunization program earlier this month, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of step with much of the global community with insufficient data for public health gain. The planned update has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

A New Direction at the Agency

The acting appointment may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for halting certain childhood shot schedules in the US to become more similar to Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, head of the FDA’s CBER – as opposed to medication approval.

Questions Over Qualifications

The appointee has no apparent track record in medication creation, regulation or administrative roles, which has been customary for previous directors of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She lacks experience in leading a major agency. She lacks background in drug approvals.”

Former commissioners of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the kind of background that prior appointees who headed the center have had.”

CDER has an immense portfolio at the agency, Woodcock stated.

“The public just pays attention on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and all of those need to be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial administrative element to the position, which supervises in excess of 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock said.

Official Statement and Controversial Programs

Regarding concerns about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “concerns are based on inaccurate assumptions”.

“Her resume matches the responsibilities of her role,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's new fast-track approval initiative, a disputed expedited therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being chosen for this fast-track system? Who takes the choices?” Howard questioned. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

In general, he said, “the FDA appears to be shifting towards more relaxed oversight of pharmaceuticals, aside from vaccines.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, critics have noted. She released a study using unverified public submissions to determine the rate of myocarditis following Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “desired changes” for the new federal leadership featured revising guidelines for recently developed shots and halting “non-essential” vaccines, she stated post-election on a audio program. At the agency, Høeg has reportedly floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She is an complete true believer who commences with her beliefs and works backwards to fit the science in a very disingenuous, dishonest way,” Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg became part of other skeptics, {like|